EMG
ACRS icon

Ellington Management Group’s Aclaris Therapeutics ACRS Stock Holding History

Ellington Management Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,800
Closed -$329K – 475
2018
Q1 		$329K Buy
+18,800
New +$398K 0.02% 554
2016
Q4 		– Sell
-9,117
Closed -$233K – 525
2016
Q3 		$233K Buy
+9,117
New +$193K 0.06% 490

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ellington Management Group's ACRS Position: Q2 2018 in Review

Ellington Management Group sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 18,800 shares — an estimated $329K sold.

Ellington Management Group first reported a position in ACRS in Q3 2016 and held it in 2 quarters. The position peaked at $329K in Q1 2018. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • Ellington Management Group reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ellington Management Group sold 18,800 Aclaris Therapeutics shares in Q2 2018, an estimated $329K.
  • Ellington Management Group first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 2 quarters.
  • Ellington Management Group's Aclaris Therapeutics position peaked at $329K in Q1 2018.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Ellington Management Group's 13F filing for Q2 2018, filed 14 Aug 2018.